Multiple Myeloma Clinical Trial
Official title:
Assessment of Percutaneous Balloon Kyphoplasty in the Treatment of Malignant Vertebral Fractures (Multiple Myeloma and Osteolytic Metastases) : "Observational Study"
Balloon Kyphoplasty is an alternative to vertebroplasty in the treatment of painful
malignant vertebral fractures. This is a mini-invasive percutaneous treatment, aiming to
stabilize the vertebral fracture, decrease of pain. This technique also improves patient
function. Namely, bedridden patients are often able to resume walking in the days following
vertebral cement injection. Advantage of Balloon Kyphoplasty as compared to vertebroplasty
is the ability to inject the cement into the diseased vertebral body which shows cortical
destruction with lower pressure, thereby possibly reducing cement leakage and related
complications.
This is a multicentric, observational prospective study. Patients are evaluated before and
after the procedure.
Sixty women or men older than 18 years, with 1 to 3 painful vertebral fracture(s) of
malignant origin (due to multiple myeloma or osteolytic vertebral metastasis) will be
enrolled. Each patient will be followed during 1 year after the procedure with 7 visits at
D-8, D-1, D1, D15, D90, D180, and D360 or until the death of the patient.
The main evaluation outcome is patient self-global satisfaction regarding the procedure on a
semi-quantitative satisfaction scale, 15 days after the Balloon Kyphoplasty.
Vertebral compression fractures (VCF) represent an important source of morbidity in patients
presenting osteolytic metastatic or myelomatous vertebral involvement. In addition, cancer
treatments may induce osteoporosis with an additional risk of vertebral fractures.
- Current medical treatments are symptomatic. They do not treat the fracture itself.
- Vertebroplasty is an interventional radiological technique that consists of injecting,
percutaneously, acrylic cement into the fractured vertebra under radiological guidance
and local or general anaesthesia, in order to combine two effects: stabilization of the
vertebral body fracture and pain reduction.
- Balloon Kyphoplasty is a variant of vertebroplasty which is performed using the KyphX®
System (Medtronic., Sunnyvale, California). Balloon kyphoplasty aims at restore
vertebral height of the fractured vertebra using an inflatable balloon prior to inject
surgical polymethylmetacrylate (PMMA)cement,into the vertebral body to fix the
fracture. It is an expensive technique costing around 4,000 euros for up to 2 vertebrae
in the same patient. The surgical technique for the procedure has been described by
LIBERMEAN et al: A bilateral approach is usually chosen to insert working cannulas into
the posterior part of the vertebral body through a posterior transpedicular approach.
In case of limited and asymmetric vertebral destruction, a single unilateral approach
may be preferred. Fluoroscopy is used to insert the tools and control the procedure.
With reaming tools, two working channels are created and the balloons are inserted. The
balloons are available in lengths of 10, 15 and 20 mm.
The two balloons (one on each side) should ideally be centered at middle height between the
superior and inferior endplates and in the anterior two-thirds of the vertebral body.
Balloon placement into the vertebral body is checked using radiopaque markers at the two
extremities of the balloon. Once inserted, the balloons are inflated using visual, volume
and pressure control to create a cavity. Inflation is stopped when one of the following
inflation endpoints is reached: pressure raised over 400 psi, balloon contacts one of the
cortical bone of the vertebra or reaching maximal balloon inflation volume. The balloons are
then deflated and removed. The mean balloon inflation volume is 2 to 3ml. The Bone Filler
Device, filled before with 1.5 ml of PMMA, is then advanced through the working cannula
towards the anterior part of the cavity and cement is slowly extruded by a stainless steel
stylet, acting as a plunger. When the amount of cement from the first Bone Filler Device is
delivered in the cavity, it is removed and another Bone Filler Device is advanced through
the working cannula. This step is repeated till a complete fill of the cavity is obtained.
The same procedure is repeated through the other working cannula at the contra-lateral
pedicle. Filling of the cavity with highly viscous PMMA is performed under continuous
fluoroscopic control.
The aim of this study is to quantify the analgesic and patient function improvement of
Balloon Kyphoplasty together with complication types and rate in patients with malignant
vertebral fractures due to metastatic disease or multiple myeloma.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |